MedPage Today (1/22, Robertson ) reports, “The risk of congenital malformations appears to be lower with buprenorphine than with methadone when taken during the first trimester of pregnancy for opioid use disorder (OUD), according to an analysis of Medicaid data.” In the study, published in JAMA Internal Medicine, “in the buprenorphine group, risk of congenital malformations was 50.9 out of 1,000 pregnancies compared with 60.6 per 1,000 in the methadone group.”
Related Links:
— MedPage Today (requires login and subscription)